Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely tapentadol (as tapentadol hydrochloride) 75 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
|
Product containing tapentadol hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
|
Tapentadol (as tapentadol hydrochloride) 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely tapentadol hydrochloride 100 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely tapentadol (as tapentadol hydrochloride) 75 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol hydrochloride 100 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol hydrochloride 100 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Tapentadol (as tapentadol hydrochloride) 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 75 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Tapentadol (as tapentadol hydrochloride) 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol hydrochloride 100 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 100 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 50 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 150 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Tapentadol (as tapentadol hydrochloride) 100 mg prolonged-release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 250 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 200 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely tapentadol (as tapentadol hydrochloride) 4 milligram/1 milliliter conventional release oral solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |
Tapentadol (as tapentadol hydrochloride) 20 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tapentadol hydrochloride |
Inferred relationship |
Some |
1 |